Viking Therapeutics COO Marianna Mancini Sells 18,217 Shares

What Happened
Marianna Mancini, Chief Operating Officer of Viking Therapeutics (VKTX), had 31,667 performance-restricted stock units (PRSU) vest on July 28, 2026 and then sold 18,217 shares in an open-market transaction on July 29, 2026 for total proceeds of approximately $609,636 (weighted avg price $33.47). The 31,667 shares were reported as an award/acquisition at $0 (vesting of PRSUs granted Jan 3, 2023; 33.33% vested upon achievement of a non‑financial performance goal).

Key Details

• Transaction dates: PRSU vesting/acquisition on 2026-07-28; open-market sale on 2026-07-29.
• Sale details: 18,217 shares sold, weighted average price $33.47, total proceeds ≈ $609,636; sale prices ranged $33.28–$33.805.
• Award details: 31,667 shares issued upon PRSU vesting (grant dated Jan 3, 2023; 33.33% vested per Footnote 1).
• Tax withholding: Some vested shares were automatically sold solely to satisfy tax-withholding obligations (Footnote 3).
• Other holdings: Filing notes inclusion of 120 shares acquired via the 2024 ESPP on May 20, 2026 (Footnote 2).
• Shares owned after transaction: Not specified in the Form 4.
• Filing timeliness: Form 4 filed 2026-07-29 for transactions on 07-28 and 07-29; filing appears timely.

Context
This was primarily a vesting event (performance RSUs) followed by sales to satisfy tax obligations and an open-market disposition. Automatic sales to cover taxes are routine and do not necessarily indicate discretionary insider selling. Purchases typically carry more interpretive weight for bullish signals; this filing documents a vesting and routine sell-down rather than an opportunistic buy.